Physician profile
Payel Gupta
NPI 1457533077
$256,109.82
in general payments reported to CMS, 2019-2025
27 companies · $81K in 2025
The $81K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,412 · 2020: $1,438 · 2021: $9,522 · 2022: $19K · 2023: $60K · 2024: $82K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $174K · Travel and Lodging: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $14K · Honoraria: $3,418 · Education: $19.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $173,523.35 |
| Travel and Lodging | $16,459.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,675.00 |
| Food and Beverage | $14,190.98 |
| Honoraria | $3,418.00 |
| Education | $19.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $61,635.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $58,764.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $38,382.55 | 2019-2025 | Shingrix, Nucala |
| Teva Pharmaceuticals USA, INC. | $19,606.38 | 2022-2025 | Airduo Digihaler, Armonair Digihaler, Proair Digihaler |
| Amgen INC. | $16,212.00 | 2022-2023 | |
| Alk-Abello, INC | $14,231.10 | 2019-2025 | Odactra |
| Genentech USA, INC. | $10,865.98 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $9,786.37 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $9,246.21 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Modernatx, INC. | $5,090.99 | 2023 | Moderna Covid-19 Vaccine |
| Arcutis Biotherapeutics, INC. | $4,722.21 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $2,965.92 | 2023-2024 | Vtama |
| Blueprint Medicines Corporation | $1,754.10 | 2022-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $486.74 | 2022-2024 | Orladeyo |
| Horizon Therapeutics Plc | $403.88 | 2022-2023 | Actimmune |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $342.81 | 2024-2025 | Hizentra, Haegarda |
| Aquestive Therapeutics, INC. | $277.08 | 2025 | |
| Pharming Healthcare, INC. | $258.36 | 2023-2025 | Ruconest |
| Optinose US, INC. | $255.52 | 2019-2020 | |
| Pfizer INC. | $254.60 | 2019-2022 | |
| Genentech, INC. | $189.21 | 2023-2024 | Xolair |
| Alcon Vision LLC | $118.74 | 2024 | Clareon |
| Regeneron Pharmaceuticals, INC. | $92.33 | 2019 | |
| Circassia INC. | $67.98 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $44.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.16 | 2020 | |
| Shire North American Group INC | $17.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payel Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.